Safety and Effectiveness of a Combination Anti-HIV Drug Treatment

NCT ID: NCT00005018

Last Updated: 2005-06-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 150 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 1999-07-31
• Study Completion Date: 2000-10-31

Brief Summary

The purpose of this study is to see if it is safe and effective to give HIV-positive patients a combination of anti-HIV drugs (abacavir [ABC] plus efavirenz [EFV] plus didanosine [ddI]) with and without hydroxyurea (HU).

Detailed Description

Patients are randomized into one of two treatment arms: ABC/EFV/ddI or ABC/EFV/ddI/HU. In the second treatment arm, patients are further randomized to receive HU beginning at Baseline, when ABC/EFV/ddI is started, or at Week 8. Delaying HU may help offset the cytopenic effect of HU, as reflected in a blunted CD4 cell response. Patients are stratified according to their screening plasma HIV-1 RNA level (400 to 10,000 copies/ml and more than 10,000 to 100,000 copies/ml). Participants in the study receive study-related exams, lab tests, and study medications at no cost over the 48-week treatment period. The safety and effectiveness of the non-protease inhibitor rescue therapy is evaluated routinely by measuring viral load and the CD4 cell count, as well as the side effects caused by the medications. All of the medications are approved by the FDA and are not considered investigational.

Conditions

HIV Infections

Keywords

HIV-1; Didanosine; Drug Therapy, Combination; Zidovudine; Stavudine; HIV Protease Inhibitors; Hydroxyurea; RNA, Viral; Reverse Transcriptase Inhibitors; Anti-HIV Agents; Viral Load; abacavir; efavirenz

Study Design

• Primary Study Purpose: TREATMENT

Interventions

Hydroxyurea

Intervention Type: DRUG

Abacavir sulfate

Intervention Type: DRUG

Efavirenz

Intervention Type: DRUG

Didanosine

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Patients may be eligible for this study if they:

• Are taking lamivudine (3TC) plus either zidovudine (ZDV) or stavudine (d4T). Patients may also be taking one or two protease inhibitors (PIs). (Patients will qualify if drug substitutions were made or if the drugs were stopped for up to 2 months under certain conditions.)
• Have a viral load of 400 copies/ml or more (treatment failure) after 16 weeks of this treatment.
• Have a viral load between 400 and 100,000 copies/ml.
• Have a CD4 cell count of 100 cells/mm3 or more.
• Have consent of a parent or guardian (if under 18).
• Agree to use a barrier form of birth control (such as condoms) during the study.
• Are at least 13 years old.

Exclusion Criteria

Patients will not be eligible for this study if they:

• Are unable to take medications by mouth.
• Have certain opportunistic (AIDS-related) infections or diseases.
• Have certain serious medical conditions such as diabetes or a disease of the liver, pancreas, or heart.
• Have a history of lymphoma.
• Have had peripheral neuropathy (a painful condition affecting the nervous system) within 2 months of study entry.
• Have been taking anti-HIV drugs for more than 1.5 years without an effect on HIV levels.
• Have ever taken ABC, ddI, or a type of anti-HIV drug called an NNRTI (such as EFV).
• Are unable to complete all 48 weeks of the study or take all of the study drugs.
• Are receiving certain other investigational treatments.
• Are receiving radiation therapy or chemotherapy within 8 weeks of study entry, or plan to receive one of these treatments during the study. (Local treatment for Kaposi's sarcoma is allowed.)
• Are taking certain medications including those that might affect the immune system or HIV levels.
• Have received a vaccine within 8 weeks of study entry or an HIV vaccine within 3 months of study entry.
• Are pregnant or breast-feeding.
• Abuse alcohol or drugs.

• Minimum Eligible Age: 13 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Glaxo Wellcome

INDUSTRY

Sponsor Role: lead

Locations

East Bay AIDS Ctr

Berkeley, California, United States

Pacific Oaks Research

Beverly Hills, California, United States

Altamed Medical Health Services

Los Angeles, California, United States

St Lukes Medical Group

San Diego, California, United States

Pacific Horizons Med Group

San Francisco, California, United States

Gary Richmond MD

Fort Lauderdale, Florida, United States

Univ of Miami School of Medicine

Miami, Florida, United States

Saint Josephs Comprehensive Research Institute

Tampa, Florida, United States

Northstar Med Clinic

Chicago, Illinois, United States

Univ of Kentucky Med Ctr

Lexington, Kentucky, United States

Boston Med Ctr / Evans - 556

Boston, Massachusetts, United States

CRI of New England

Brookline, Massachusetts, United States

Univ of Nebraska Medical Ctr

Omaha, Nebraska, United States

Beth Israel Med Ctr

New York, New York, United States

Saint Luke's - Roosevelt Hosp Ctr

New York, New York, United States

Univ of North Carolina / Infectious Disease Division

Chapel Hill, North Carolina, United States

Univ of NC Infectious Diseases

Wilmington, North Carolina, United States

Anderson Clinical Research Inc

Reading, Pennsylvania, United States

Miriam Hosp

Providence, Rhode Island, United States

Burnside Clinic

Columbia, South Carolina, United States

Univ of Texas Med Branch

Galveston, Texas, United States

Univ of Texas / Thomas Street Clinic

Houston, Texas, United States

Hampton Roads Med Specialists

Hampton, Virginia, United States

Countries

United States

Other Identifiers

NZTA4008

Identifier Type: -

Identifier Source: secondary_id

238R

Identifier Type: -

Identifier Source: org_study_id